
## WHAT IS CLAIMED IS:

A compound of formula (I): 1.



wherein  $R^1$  is -Z-A wherein Z is (a)  $C_1$ - $C_7$  alkyl, optionally comprising 1-2 double bonds, 1-2 nonperoxide O or 1-2 NR wherein R is individually H, phenyl, benzyl,  $C_2-C_4 \text{ alkanoyl or } C_1-C_6 \text{ alkyl; (b) } C_3-C_6 \text{ cycloalkyl; (c) } C_3-C_6 \text{ cycloalkyl } C_1-C_3 \text{ alkyl; (b) } C_3-C_6 \text{ cycloalkyl; (c) } C_3-C_6 \text{ cycloalkyl; (d) } C_3-$ (d)  $C_6$ - $C_{10}$  aryl; or (e)  $C_6$ - $C_{10}$  aryl  $C_k$ - $C_3$  alkyl;

**(I)** 

A is  $N(R)_2$ ,  $C_2$ - $C_4$  acyloxy,  $SO_3H$ ,  $PO_4H_2$ , NNO(OH),  $SO_2NH_2$ ,  $PO(OH)NH_2$ , OH, SO<sub>2</sub>R<sup>3</sup> tetrazolyl, or COOR<sup>3</sup> wherein R<sup>3</sup> is H, phenyl, benzyl or C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 1-2 OR, C<sub>6</sub>-C<sub>10</sub> heteroaryl, C<sub>6</sub>-C<sub>10</sub> aryl, C<sub>2</sub>-C<sub>4</sub> alkenyl, phenyl, tetrazolyl or OZ wherein Z is an ester of an amino acid;

 $R^2$  is a  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_6$ - $C_{10}$  aryl  $C_1$ - $C_2$  alkyl or  $C_6$ - $C_{10}$ heteroaryl C<sub>1</sub>-C<sub>2</sub> alkyl;

X is H, halo, OR, SR, N<sub>3</sub> or N(R)<sub>2</sub>; or a pharmaceutically acceptable salt thereof.

- 2. The compound of claim 1 wherein Z is  $(C_2-C_6)$  alkyl or phenyl.
- The compound of claim 1 or 2 wherein A is CO<sub>2</sub>R. 3.
- The compound of claim 3 wherein R3 is H or (C1-C6)alkyl, optionally substituted with OH, C<sub>6</sub>-C<sub>10</sub> heteroaryl or OZ, wherein Z is an ester of an amino acid.

a

- 5. The compound of claim 4 wherein Z is an L-valine residue or L-glycine residue.
- 6. The compound of claim 4 wherein Z is 4-pyridyl.
- 7. The compound of claim 1 or 2 wherein R<sup>1</sup> is ethoxycarbonylpropyl.
- 8. The compound of claim 1 or 2 wherein X is NH<sub>2</sub>.
- 9. The compound of claim 1 or 2 wherein  $R^2$  is  $CH_3$  or  $CH_2CH_2CH_3$ .
- 10. A pharmaceutical composition comprising the compound of claim 1 in combination with a pharmaceutically acceptable carrier.
- 11. A therapeutical method for treating a pathological condition associated with TNFα release comprising administering to a mammal in need of such treatment an amount of a compound of claim 1 effective to treat said pathological condition.
- 12. The method of claim 1)1 wherein said condition comprises a pathological inflammatory response.
- The method of claim 12 wherein said inflammatory response is due to arthritis.
- 14. The method of claim 12 wherein said inflammatory response is due to an autoimmune disease.
- 15. The method of claim 14 wherein said autoimmune disease is rheumatoid arthritis, multiple sclerosis, asthma, psoriasis or inflammatory bowel disease.

- 16. The method of claim 11 wherein said condition comprises cardiomyopathy or congestive heart failure.
- 17. The method of claim 11 wherein said condition comprises insulin-resistant diabetes.